

## CONTRACEPTION

### AUTHOR INDEX Volume 30 July - December 1984

- Abdalla, S.A., 413  
Abdel-Aleem, A.M., 391  
Alvarez, F., 443  
Amatayakul, K., 179  
Amortegui, A.J., 135  
Astedt, B., 355  
Atienza, M.F., 99, 215  
Back, D.J., 89, 289  
Balogh, S., 209  
Bélanger, A., 483, 585  
Bergink, E.W., 61  
Bergquist, C., 107  
Blache, D., 279  
Brache, V., 443  
Breckenridge, A.M., 289  
Burkman, R.T., 99, 215  
Carmassi, F., 575  
Casado, M.E., 311  
Chan, S.Y.W., 363  
Chi, I.-C., 209  
Ciavatti, M., 279  
Collins, J.A., 457  
Cordell, G.A., 253  
Coutinho, E., 443  
Croxatto, H.B., 311  
Cullberg, G., 75  
Darwish, H.A., 413  
Davenas, E., 279  
Delezé, M., 29  
Diaz, J., 443  
Diaz, M.M., 443  
Diaz, S., 311, 443  
Diaz-Sánchez, V., 371  
Doong, R.L., 271  
Duffy, T.J., 197  
Elder, M.G., 55  
El-Kabsh, M.Y., 421  
El Mahgoub, S., 125, 443  
El-Nashar, I.M., 391  
El-Sharkawy, M.M., 407  
El Shourbagy, M., 125  
El Tawil, A., 125  
Elwan, S.I., 407, 413, 421  
El Zeniny, A., 125  
Embil, J.A., 457  
Farghaly, A.S., 407, 421  
Faundes, A., 443  
Fianu, A., 23  
Fioretti, P., 575  
Fong, H.H.S., 253  
Ford, S.A., 261  
Fotherby, K., 55  
Frizzetti, F., 575  
Garza-Flores, J., 371  
Ghaneimah, S.A., 391  
Giasson, M., 585  
Gillett, P.G., 457  
Goldsmith, A., 161  
Gomaa, A.A., 391  
Gray, R.H., 297  
Grimmer, S.F.M., 289  
Gudmundsson, J.A., 107  
Guillebaud, J., 535  
Gutiérrez, G., 29  
Hagen, D.F., 545  
Hahn, D.W., 39  
Hamawi, A., 55  
Herreros, C., 311  
Honore, L.H., 555  
Indian Council of Medical Research Task Force on Female Sterilization, 339  
Indian Council of Medical Research Task Force on Hormonal Contraception, 561  
Jimenez, J., 523  
Jimenez-Thomas, S., 371  
Johannesson, E., 225  
Jonasson, A., 23  
Jones, A.R., 261  
Juez, G., 311  
Kim, I.C., 253  
Kindahl, H., 23  
King, T.M., 99, 215  
Kirk, M.E., 457  
Kjaeldgaard, A., 169, 355  
Kloosterboer, H.J., 61  
Kuhl, H., 467  
Kurunmäki, H., 381, 431  
Labrie, F., 585

## CONTRACEPTION

- Lacoste, D., 585  
Lähteenmäki, P., 381  
Lähteenmäki, P.L.A., 143,  
381, 431  
Landgren, B.-M., 225  
Larsson, B., 23, 169, 355  
Lawson, J.P., 55  
Lee, R.J., 115  
Lee, S.-Y., 545  
Lehfeldt, H., 331  
Lenker, R.M., 327  
Lindberg, M.C., 81, 599  
Lucas, S., 55  
Lund, L., 61  
Luukkainen, T., 381, 431  
Mao, K., 535  
Marcelle, G.B., 253  
Matlin, S.A., 253  
Mattos, C.E.R., 443  
McGuire, J.L., 39  
Mehlis, W., 467  
Melder, R.O., 135  
Melis, G.B., 575  
Meyer, M.P., 135  
Mintz, G., 29  
Miranda, P., 311  
Mitra, S.B., 81, 599  
Naqvi, R.H., 81, 599  
Nillius, S.J., 107  
Nummi, S., 61  
Ochoa, M., 523  
Ölund, A., 23  
Orme, M.L'E., 289  
Paoletti, A.M., 575  
Pavez, M., 443  
Peralta, O., 311  
Perlin, I.A., 457  
Pilla, L., 253  
Pirkle, W.H., 253  
Portales, P., 523  
Program for Applied Research  
on Fertility Regulation, 239  
Purba, H.S., 289  
Ray, R., 197  
Renaud, S., 279  
Resch, B., 153  
Richards, G., 457  
Rodríguez, E., 29  
Rosenthal, M.E., 39  
Ruckphaopunt, S., 179  
Rudel, H.W., 371  
Saksena, I.-F., 81  
Salah, M., 391  
Salvaterra, A.M., 311  
Sandow, J., 467  
Sas, M., 153  
Shaaban, M.M., 391, 407, 413, 421  
Singh, B., 135  
Singhamani, R., 179  
Sivin, I., 331, 443  
Smith, G.G., 115  
Soler, M.P., 523  
Stern, J., 443  
Stumpf, P.G., 327  
Tang, L.C.H., 363  
Taubert, H.-D., 457  
Thabet, N., 421  
Tobia, A.J., 39  
Toivonen, J., 381, 431  
Traub, A., 153  
Trayner, I., 55  
Tremblay, Y., 483, 585  
Ugocsai, G., 153  
Uttaravichai, C., 179  
Waller, D.P., 253  
Weber, W., 467  
World Health Organization  
Task Force on Intrauterine  
Devices, 1  
World Health Organization  
Task Force on Oral  
Contraceptives, 505  
Wu, J.T., 271  
Xiao-Nian, M., 89  
Zalányi, S., 225  
Zaneveld, L.J.D., 161  
Zayid, I., 457

## CONTRACEPTION

### SUBJECT INDEX Volume 30 July - December 1984

- Abortion,  
    association with pelvic inflammatory disease, 1  
    morbidity risk among young adolescents, 99
- Actinomycetes-like organisms, prevalence in cervical smears from IUD users, 535
- Adhesions,  
    effect of intrauterine quinacrine (monkey), 161  
    effect of intrauterine tetracycline (monkey), 161
- Adolescents, morbidity risk at time of elective abortion, 99
- Adverse pregnancy outcomes, aged gametes and Natural Family Planning, 297
- Aged gametes, adverse pregnancy outcomes and Natural Family Planning, 297
- Albumin level, effect of levonorgestrel, 407
- Alkaline phosphatase activity, effect of levonorgestrel, 407
- Aminopyrine N-demethylase activity, effect of gossypol (rat), 89
- Androst-5-ene-3 $\alpha$ ,17 $\beta$ -diol level,  
    effect of [D-Tryp $^6$ ]LHRH ethylamide (dog), 483, 585  
    effect of [D-Tryp $^6$ ]LHRH ethylamide + testosterone (dog), 585
- Androstan-3 $\beta$ ,17 $\beta$ -diol level,  
    effect of [D-Tryp $^6$ ]LHRH ethylamide (dog), 483, 585  
    effect of [D-Tryp $^6$ ]LHRH ethylamide + testosterone (dog), 585
- Androstan-3 $\beta$ ,17 $\beta$ -diol level,  
    effect of [D-Tryp $^6$ ]LHRH ethylamide (dog), 483, 585  
    effect of [D-Tryp $^6$ ]LHRH ethylamide + testosterone (dog), 585
- Androstanedione level,  
    effect of [D-Tryp $^6$ ]LHRH ethylamide (dog), 483, 585  
    effect of [D-Tryp $^6$ ]LHRH ethylamide + testosterone (dog), 585
- Antifertility activity, effect of ORF 13811 (variety of biological test systems), 39
- Antimotility effect on spermatozoa, ( $\pm$ )-gossypol, (+)-gossypol, (-)-gossypol and gossypolone, 255
- Antithrombin III level,  
    effect of ethinylestradiol + levonorgestrel, 421  
    effect of levonorgestrel, 421  
    effect of mestranol + norethisterone, 421
- $\alpha_1$  Antitrypsin level,  
    effect of ethinylestradiol + levonorgestrel, 421  
    effect of levonorgestrel, 421  
    effect of mestranol + norethisterone, 421
- Apolipoprotein A-I level,  
    effect of ethynodiol + desogestrel, 61  
    effect of ethynodiol + levonorgestrel, 61
- Apolipoprotein B level,  
    effect of ethynodiol + desogestrel, 61  
    effect of ethynodiol + levonorgestrel, 61
- Apolipoprotein B/apolipoprotein A-I ratio,  
    effect of ethynodiol + desogestrel, 61  
    effect of ethynodiol + levonorgestrel, 61
- Barrier or natural method users, microbiological and histological findings in the fallopian tubes, 457
- Betadine, effect on metabolic activity of *Ureaplasma urealyticum*, 135

## CONTRACEPTION

- Bile acids level, effect of levonorgestrel, 407
- Bilirubin level, effect of levonorgestrel, 407
- Biological investigation, effect of d-norgestrel (rabbit), 153
- Birth defects, epidemiologic review of Natural Family Planning, 297
- Blastocysts, effect of CI-628 on morphology and  $17\beta$ -hydroxysteroid dehydrogenase activity (mouse), 271
- Bleeding pattern,
  - effect of levonorgestrel, 391
  - effect of levonorgestrel-releasing IUD, 443
  - effect of naftarelin, 107
  - effect of norethindrone, 239
  - effect of norethisterone enanthate, 225
  - effect of TCu 380Ag, 443
  - use of Copper T200, 311
  - use of progesterone pellets, 311
- Blood coagulation,
  - effect of ethinylestradiol + levonorgestrel, 421
  - effect of levonorgestrel implants, 421
  - effect of mestranol + norethisterone, 421
- Blood pressure,
  - effect of levonorgestrel, 413
  - effect of norethisterone oenanthate, 561
- Body weight,
  - effect of ethinylestradiol (rat), 169
  - effect of ethinyl estradiol + levonorgestrel and multivitamin supplementation, 179
  - effect of gossypol (rat), 89
  - effect of levonorgestrel, 413
  - effect of norethisterone oenanthate, 561
  - effect of d-norgestrel (rat), 169
- Body weight vs method failures, use of norethisterone oenanthate, 561
- Breakthrough bleeding, effect of ethinylestradiol + norethisterone, 371
- Breast-feeding duration, effect of depot-medroxyprogesterone acetate, 523
- Breast feeding status,
  - use of Copper T200, 311
  - use of progesterone pellets, 311
- Cardiovascular pharmacology,
  - effect of ORF 13811 (variety of biological test systems), 39
  - effect of PGF<sub>2</sub> $\alpha$  (variety of biological test systems), 39
- Carotenoids level, effect of ethinyl estradiol + levonorgestrel and multivitamin supplementation, 179
- Cavity rim cap, use effectiveness, 331
- Cavity-rim cervical cap, survey of use and efficacy, 115
- Ceruloplasmin level,
  - effect of desogestrel, 73
  - effect of levonorgestrel, 407
  - effect of lynestrenol, 73
- Cervical cap,
  - survey of use and efficacy, 115
  - use effectiveness, 331
- Cervical dilatation by laminaria, effect on 15-keto-13,14-dihydro-PGF<sub>2</sub> $\alpha$  level, 23
- Cervical smears, prevalence of actinomycetes-like organisms in IUCD users, 535

## CONTRACEPTION

- Cervix, microbiological findings in women using various contraceptive methods, 457
- Cesarean section, performance of interval insertion of IUDs, 209
- Chlormadinone acetate,  
    effect of basal LH concentrations (rat), 467  
    effect of LH-RH-stimulated LH release (rat), 467
- 6-Chloro-6-deoxyglucose, effect on metabolism of spermatozoa (guinea pig), 261
- (R)- $\alpha$ -Chlorohydrin, effect on metabolism of spermatozoa (guinea pig), 261
- (S)- $\alpha$ -Chlorohydrin, effect on metabolism of spermatozoa (guinea pig), 261
- (R,S)-3-Chlorolactaldehyde, effect on metabolism of spermatozoa (guinea pig), 261
- Chloroquine, effect on pharmacokinetics of ethinyloestradiol + levonorgestrel, 289
- CI-628 (1-[2-( $\alpha$ -(*p*-methoxyphenyl)- $\beta$ -nitrostyryl]phenoxy)ethyl]-pyrrolidine, monocitrate), effect on morphology and 17 $\beta$ -hydroxysteroid dehydrogenase activity of blastocysts (mouse), 271
- Clinical outcome, urea + PGF<sub>2</sub> $\alpha$  with osmotic dilator or laminaria tent for midtrimester abortion, 215
- Clotting factors II, V, VII through XIII,  
    effect of ethynodiol + levonorgestrel, 421  
    effect of levonorgestrel, 421  
    effect of mestranol + norethisterone, 421
- Complementary food in addition to breast milk, effect of hormonal contraceptives in lactating women, 505
- Complications,  
    laparoscopic tubal sterilization in a free-standing clinic, 545  
    relative risk for adolescents undergoing elective abortion, 99  
    tubal sterilization with Filshie Clip, 339  
    urea + PGF 2 $\alpha$  with osmotic dilator or laminaria tent for midtrimester abortion, 215
- Conceptrol, effect on metabolic activity of *Ureaplasma urealyticum*, 135
- Continuation rate,  
    effect of insertion technique in postpartum IUD insertion, 327  
    interval insertion of IUD in women with previous cesarean section, 209  
    use of cavity rim cap, 331  
    use of levonorgestrel-releasing IUD, 443  
    use of norethisterone enanthate 60±5-day or 90±5-day schedule, 561  
    use of TCu 380Ag, 443
- Contraceptive use, association with pelvic inflammatory disease, 1
- Contraceptive vaginal ring, ST-1435-releasing, 381
- Conventional contraceptive use, association with pelvic inflammatory disease, 1
- Copper 7, case report of placental candidiasis with IUCD in situ, 555
- Copper IUCD, prevalence of actinomycetes-like organisms in cervical smears, 535
- Copper T, performance in women with previous cesarean section, 209
- Copper T200, fertility regulation in nursing women, 311
- Cord morphology and histology, case reports of placental candidiasis, 555
- Cortisol binding globulin level,  
    effect of desogestrel, 73  
    effect of lynestrenol, 73
- Counselling leaflet on actinomycetes-like organisms in cervical smears, 535
- Cycle length, effect of ethynodiol + norethisterone, 371

## CONTRACEPTION

- Cyproterone acetate,  
    effect on basal LH concentrations (rat), 467  
    effect on LH-RH-stimulated LH release (rat), 467
- Cytochrome P450 level, effect of gossypol (rat), 89
- Dehydroepiandrosterone level,  
    effect of [D-Tryp<sup>6</sup>]LHRH ethylamide (dog), 483, 585  
    effect of [D-Tryp<sup>6</sup>]LHRH ethylamide + testosterone (dog), 585
- Delfen Foam, effect on metabolic activity of Ureaplasma urealyticum, 135
- Depot-medroxyprogesterone acetate,  
    effect on development and health of breast-fed children, 523  
    effect on milk volume and infant growth, 505
- Desogestrel (17 $\alpha$ -ethynodiol-18-methyl-11-methylene-4-estrene-17 $\beta$ -ol),  
    effect on basal LH concentrations (rat), 467  
    effect on LH-RH-stimulated LH release (rat), 467  
    effect on proteins and vaginal cytology, 73
- Development of breast-fed children, effect of depot-medroxyprogesterone acetate in lactating women, 523
- Diabetes mellitus, effect of oral contraceptive use, 197
- Diabetic signs and symptoms, effect of oral contraceptive use, 197
- Dihydrotestosterone level,  
    effect of [D-Tryp<sup>6</sup>]LHRH ethylamide (dog), 483, 585  
    effect of [D-Tryp<sup>6</sup>]LHRH ethylamide + testosterone, 585
- Dilatation of cervix by laminaria tents,  
    clinical evaluations, 215  
    effect on 15-keto-13,14-dihydro-PGF<sub>2</sub> $\alpha$  level, 23
- Dilatation of cervix by osmotic dilators, clinical evaluations, 215
- Discontinuation rate,  
    use of hormonal contraceptives in lactating women, 505  
    use of norethisterone enanthate 60 $\pm$ 5-day or 90 $\pm$ 5-day schedule, 561
- Dislodgement,  
    use of cavity rim cap, 331  
    use of cervical cap, 115
- Dose of levonorgestrel,  
    effect on kinetic parameters (rat), 599  
    effect on pharmacokinetic parameters (rat), 599
- Dose- and time-dependent alterations of basal and LH-RH-stimulated LH release,  
    treatment with various hormonal contraceptives (rat), 467
- Effectiveness, progesterone implants in nursing women, 311
- Ejaculate volume,  
    effect of [D-Tryp<sup>6</sup>]LHRH ethylamide (dog), 585  
    effect of [D-Tryp<sup>6</sup>]LHRH ethylamide + testosterone (dog), 585
- Emko Foam, effect on metabolic activity of Ureaplasma urealyticum, 135
- Encare oval, effect on metabolic activity of Ureaplasma urealyticum, 135
- Endocrine functions, effect of norethindrone, 239
- Endometrial activity, effect of norethisterone enanthate, 225
- Endometrial changes,  
    effect of intrauterine quinacrine (monkey), 161  
    effect of intrauterine tetracycline (monkey), 161
- Endometrial dating, effect of tubal sterilization, 125
- Endometrium, effect of d-norgestrel (rabbit), 153
- Epidemiologic review, aged gametes, adverse pregnancy outcomes and Natural Family Planning, 297

## CONTRACEPTION

- Erosion, laceration or pelvic inflammatory disease, use of cavity rim cap, 331
- Estradiol level,  
effect of desogestrel, 73  
effect of levonorgestrel, 391, 431  
effect of lynestrenol, 73  
effect of nafarelin, 107  
effect of norethisterone enanthate, 225  
effect of [D-Tryp<sup>5</sup>]LHRH ethylamide (dog), 585  
effect of [D-Tryp<sup>6</sup>]LHRH ethylamide + testosterone (dog), 585
- Estrogen deficiency symptoms, effect of nafarelin, 107
- Estrone, effect of CI-628 on production by blastocysts (mouse), 271
- Ethinylestradiol,  
dissolution rates of different crystal sizes, 371  
effect on basal LH concentrations (rat), 467  
effect on fibrinolytic activity in plasma and vessel walls of hind leg (rat), 169  
effect on LH-RH-stimulated LH release (rat), 467  
effect on release of tissue-type plasminogen activator, 355
- Ethinyl estradiol + chlormadinone acetate,  
effect on basal LH concentrations (rat), 467  
effect on LH-RH-stimulated LH release (rat), 467
- Ethinyl estradiol + cyproterone acetate,  
effect on basal LH concentrations (rat), 467  
effect on LH-RH-stimulated LH release (rat), 467
- Ethinyl estradiol + desogestrel,  
effect on basal LH concentrations (rat), 467  
effect on Fibrinopeptide A levels, 575  
effect on LH-RH-stimulated LH release (rat), 467
- Ethinylestradiol + gestoden, effect on Fibrinopeptide A levels, 575
- Ethinylestradiol + levonorgestrel,  
effect on blood coagulation, 421  
effect on milk volume and infant growth, 505  
effect on vitamin metabolism and effects of multivitamin supplementation, 179
- Ethinylestradiol + norethisterone,  
clinical parameters after administration, 371  
development of a low-dose monthly injectable contraceptive, 371  
effect on basal LH concentrations (rat), 467  
effect on LH-RH-stimulated LH release (rat), 467
- Ethinyl estradiol + norgestrel,  
effect on basal LH concentrations (rat), 467  
effect on LH-RH-stimulated LH release (rat), 467
- Ethinylestradiol + d-norgestrel, effect on release of tissue-type plasminogen activator, 355
- Ethinylestradiol level, after subcutaneous injection of ethinylestradiol (rat), 169,
- Ethinylestradiol metabolism, effect of gossypol (rat), 89
- Ethinylestradiol + desogestrel, effect on lipids, apolipoproteins and glycosylated proteins, 61
- Ethinylestradiol + levonorgestrel,  
effect on lipids, apolipoproteins and glycosylated proteins, 61  
pharmacokinetics following administration of primaquine and chloroquine, 289

## CONTRACEPTION

- Ethinylestradiol level, after oral administration of ethinylestradiol + levonorgestrel, 289
- Ethynelestradiol, effect on platelet lipid biosynthesis and aggregation with normal or vitamin E-deficient diet (rat), 279
- Ethynelestradiol +  $\alpha$ -tocopherol acetate, effect on platelet lipid biosynthesis and aggregation with normal or vitamin E-deficient diet (rat), 279
- Expulsion,
  - use of levonorgestrel-releasing IUD, 443
  - use of TCu 380Ag, 443
- Expulsion rate,
  - effect of insertion technique in postpartum IUD insertion, 327
  - interval insertion of IUD in women with previous cesarean section, 209
- Failure rate, tubal sterilization with Filshtie Clip, 339
- Fallopian tubes, microbiological and histological findings in women using various contraceptive methods, 457
- Fertility, following removal of levonorgestrel implants, 431
- Fertility regulating agents, association with pelvic inflammatory disease, 1
- Fertility regulation in nursing women, progestrone implants, 311
- Fertilizing capacity of spermatozoa, effect of reserpine, 363
- Fibrinogen level,
  - effect of ethinylestradiol + levonorgestrel, 421
  - effect of levonorgestrel, 421
  - effect of mestranol + norethisterone, 421
- Fibrinolytic activity,
  - effect of ethinylestradiol (rat), 169
  - effect of d-norgestrel (rat), 169
- Fibrinopeptide A level,
  - during different phases of menstrual cycle, 575
  - effect of ethinylestradiol + desogestrel, 575
  - effect of ethinylestradiol + gestoden, 575
- Filshtie Clip Mark IV, use in tubal sterilization, 339
- First trimester abortion, cervical dilatation by laminaria, 23
- Fitting and insertion, cavity rim cap, 331
- Folate level, effect of ethinyl estradiol + levonorgestrel and multivitamin supplementation, 179
- Follow-up of IUCD users with actinomycetes-like organisms in cervical smears, 535
- Follow-up rate, interval insertion of IUD in women with previous cesarean section, 209
- Free-standing clinic, experience with laparoscopic tubal sterilizations, 545
- FSH (follicle stimulating hormone)
- FSH level, effect of levonorgestrel, 391, 431
- Genital tract morphology,
  - effect of intrauterine quinacrine (monkey) 161
  - effect of intrauterine tetracycline (monkey), 161
- Glucose tolerance test,
  - effect of intravaginal ring releasing levonorgestrel, 55
  - effect of oral contraceptive use, 197
- Glutamic oxalacetic transaminase activity, effect of levonorgestrel, 407
- Glutamic pyruvic transaminase activity, effect of levonorgestrel, 407
- $\gamma$ -Glutamyl transferase activity, effect of levonorgestrel, 407

## CONTRACEPTION

- Glycosylated proteins level,  
    effect of ethynodiol + desogestrel, 61  
    effect of ethynodiol + levonorgestrel, 61
- GnRH (gonadotropin-releasing hormone)
- GnRH agonist, nafarelin, 107
- Gonadal functions, effect of [D-Tryp<sup>6</sup>]LHRH ethylamide (dog), 483
- Gossypol, effect on hepatic microsomal enzymes (rat), 89  
(-)-Gossypol, spermicidal effect, 253  
(+)-Gossypol, spermicidal effect, 253  
(±)-Gossypol, spermicidal effect, 253
- Gossypolone, spermicidal effect, 253
- Growth of breast-fed children, effect of depot-medroxyprogesterone acetate in lactating women, 523
- Growth of breast fed infants,  
    use of Copper T200, 311  
    use of progesterone pellets, 311
- Haemoglobin, effect of ethynodiol + levonorgestrel and multivitamin supplementation, 179
- Haptoglobin level, effect of levonorgestrel, 407
- hCG (human chorionic gonadotropin)
- hCG/LH level, immediate postabortal use of levonorgestrel implants, 431
- HDL-C (high-density lipoprotein cholesterol)
- HDL-C level,  
    effect of ethynodiol + desogestrel, 61  
    effect of ethynodiol + levonorgestrel, 61  
    effect of levonorgestrel, 55, 413
- HDL-C/TC - HDL-C ratio, effect of levonorgestrel, 413
- Health status of breast-fed children, effect of depot-medroxyprogesterone acetate in lactating women, 523
- Hemoglobin level,  
    effect of levonorgestrel-releasing IUD, 443  
    effect of TCu 380 AG, 443  
    use of norethisterone oenanthate, 561
- Hemopexin level, effect of levonorgestrel, 407
- Hepatic microsomal enzymes, effect of gossypol (rat), 89
- Histological and microbiological findings in fallopian tubes,  
    oral contraceptive pill users, 457  
    use of IUDs, 457  
    use of natural or barrier methods of contraception, 457
- Histology and morphology of cord, case reports of placental candidiasis, 555
- Hormonal changes, levonorgestrel implants, 391
- Hormonal contraceptive, effect on milk volume and infant growth, 505
- 17-Hydroxypregnенолон level,  
    effect of [D-Tryp<sup>6</sup>]LHRH ethylamide (dog), 585  
    effect of [D-Tryp<sup>6</sup>]LHRH ethylamide + testosterone (dog), 585
- 17-Hydroxyprogesterone level,  
    effect of [D-Tryp<sup>6</sup>]LHRH ethylamide (dog), 483, 585  
    effect of [D-Tryp<sup>6</sup>]LHRH ethylamide + testosterone (dog), 585
- 17 $\beta$ -Hydroxysteroid dehydrogenase, effect on activity of blastocysts by CI-628 (mouse), 271
- Immediate postabortal contraception, levonorgestrel implants, 431
- Immobilization of spermatozoa, effect of (±)-gossypol, (+)-gossypol, (-)-gossypol and gossypolone, 253
- Immunoglobulin G, M, and A, effect of levonorgestrel, 407

## CONTRACEPTION

- Impaired glucose tolerance, effect of oral contraceptive use, 197  
Implant contraceptive,  
    levonorgestrel, 391, 407, 413, 421, 431  
    norethindrone, 239  
    progesterone, 311  
Implantation, effect of ORF 13811 (variety of biological test systems), 39  
Inert IUCD, prevalence of actinomycetes-like organisms in cervical smears, 535  
Infant growth and milk volume,  
    effect of ethinyl estradiol + levonorgestrel, 505  
    effect of depot-medroxyprogesterone acetate, 505  
    effect of dl-norgestrel, 505  
Infant weight, effect of hormonal contraceptives in lactating women, 505  
Inflammation in fallopian tubes, findings in women using various  
    contraceptive methods, 457  
Injectable contraceptive,  
    ethynodiol-diol + norethisterone, 371  
    depot-medroxyprogesterone acetate, 505, 523  
    norethisterone enanthate, 29, 225, 561  
Injection-abortion interval, urea + PGF<sub>2α</sub> with osmotic dilator or  
    laminaria tent for midtrimester abortion, 215  
Insertion characteristics,  
    levonorgestrel-releasing IUD, 443  
    TCu 380Ag, 443  
Insertion technique, effect on expulsion rate of postpartum IUD insertion, 327  
Insulin or oral agent users, effect of oral contraceptives, 197  
Interval IUD insertion, women with previous cesarean section, 209  
Intestinal absorption, ST-1435 (rat), 143  
Intranasal contraceptive, naftarelin, 107  
Intrauterine contraceptive device (IUCD or IUD),  
    copper, 535  
    copper 7, 555  
    Copper T, 209  
    Copper T200, 311  
    effect on vitamin metabolism, 179  
    inert, 535  
    levonorgestrel-releasing, 443  
    Lippes Loop, 209  
    modified Lippes type, 327  
    Multiload, 209  
    performance in women with previous cesarean section, 209  
    prevalence of actinomycetes-like organisms in cervical smears, 535  
    TCu 380Ag, 443  
Intrauterine quinacrine pellets and tetracycline tablets, effect on tubal  
    occlusion (monkey), 161  
Intravaginal chemical contraceptives, effect on metabolic activity of  
    *Ureaplasma urealyticum*, 135  
Intravaginal ring, releasing levonorgestrel, 55  
IUCD or IUD (intrauterine contraceptive device)  
IUD insertion immediate postpartum, effect of insertion technique on  
    expulsion rate, 327  
IUD use,  
    association with pelvic inflammatory disease, 1  
    microbiological and histological findings in the fallopian tubes, 457

## CONTRACEPTION

- 15-Keto-13,14-dihydro-PGF<sub>2 $\alpha$</sub>  level, effect of cervical dilatation by laminaria, 23  
Kinetic parameters, effect of subcutaneous administration of various doses of levonorgestrel (rat), 599  
Koromex II, effect on metabolic activity of Ureaplasma urealyticum, 135  
Laminaria tents for cervical dilatation  
    clinical evaluations, 215  
    effect on 15-keto-13,14-dihydro-PGF<sub>2 $\alpha$</sub>  level, 23  
Lanosterol, effect on platelet aggregation (rat), 279  
Lanosterol +  $\alpha$ -tocopherol, effect on platelet aggregation (rat), 279  
Laparoscopic tubal sterilization in a free-standing clinic, 545  
Laparotomy findings, effect of d-norgestrel (rabbit), 153  
LDL-C (low-density lipoprotein cholesterol)  
LDL-C level, effect of levonorgestrel, 55, 413  
Levonorgestrel,  
    effect on basal LH concentrations (rat), 467  
    effect on LH-RH-stimulated LH release (rat), 467  
    intravaginal ring, 55  
    pharmacokinetics (rat), 81, 599  
    radioimmunoassay, 81  
    use in women with systemic lupus erythematosus, 29  
Levonorgestrel implant,  
    effect on blood coagulation, 421  
    effect on liver functions, 407  
    effect on serum lipids, 413  
    hormonal changes, 391  
    immediate postabortal contraception, 431  
Levonorgestrel level,  
    after intravenous administration of levonorgestrel (rat), 81  
    after oral administration of ethynodiol + levonorgestrel, 289  
    effect of subcutaneous administration of various doses (rat), 599  
    use of levonorgestrel implants, 391, 431  
Levonorgestrel-releasing intravaginal ring, effect on lipid levels and glucose tolerance, 55  
Levonorgestrel-releasing IUD, effectiveness, 443  
LH (luteinizing hormone)  
LH level,  
    effect of levonorgestrel, 391, 431  
    effect of norethindrone, 239  
LH release during treatment with various hormonal contraceptives, time- and dose-dependent alterations (rat), 467  
LH-RH (luteinizing hormone releasing hormone)  
LHRH agonist, [D-Tryp<sup>6</sup>,des-Gly-NH<sub>2</sub><sup>10</sup>]LHRH ethylamide, 483, 585  
LH-RH-stimulated LH release during treatment with various hormonal contraceptives, time- and dose-dependent alterations (rat), 467  
Lipids,  
    effect of ethynodiol + desogestrel, 61  
    effect of ethynodiol + levonorgestrel, 61  
    effect of intravaginal ring releasing levonorgestrel, 55  
    effect of levonorgestrel implants, 413  
Lippes Loop, performance in women with previous cesarean section, 209  
Lippes type IUD modified for immediate postpartum insertion, effect of  
    insertion technique and expulsion rate, 327  
Liver functions, effect of levonorgestrel implants, 407

## CONTRACEPTION

- Liver weight, effect of gossypol (rat), 89  
Luteal function, following tubal sterilization, 125  
Lynestrenol, effect on proteins and vaginal cytology, 73  
 $\alpha_2$  Macroglobulin level,  
    effect of ethinylestradiol + levonorgestrel, 421  
    effect of levonorgestrel, 421  
    effect of mestranol + norethisterone, 421  
Management of actinomycetes-like organisms in cervical smears of IUD users, 535  
Management of failures, tubal sterilization with Filshie Clip, 339  
Maturation value of vaginal cytology  
    effect of desogestrel, 73  
    effect of lynestrenol, 73  
Menses induction, effect of ORF 13811 (baboon), 39  
Menstrual changes, following tubal sterilization, 125  
Menstrual cycle, Fibrinopeptide A levels during different phases, 575  
Menstrual disturbances, use of norethisterone oenanthate 60 $\pm$ 5-day or  
    90 $\pm$ 5-day schedule, 561  
Menstrual patterns and pain  
    use of levonorgestrel-releasing IUD, 443  
    use of TCu 380Ag, 443  
Mestranol + norethisterone, effect of blood coagulation, 421  
Metabolic functions, effect of norethindrone, 239  
Metabolism of spermatozoa  
    effect of 6-chloro-6-deoxyglucose (guinea pig), 261  
    effect of (R)- $\alpha$ -chlorhydrin (guinea pig), 261  
    effect of (S)- $\alpha$ -chlorhydrin (guinea pig), 261  
    effect of (R,S)-3-chlorolactaldehyde (guinea pig), 261  
Method failure, use of norethisterone oenanthate, 561  
Microbiological and histological findings in fallopian tubes,  
    oral contraceptive pill users, 457  
    use of IUDs, 457  
    use of natural or barrier methods of contraception, 457  
Microscopic investigation, effect of d-norgestrel (rabbit), 153  
Microsomal protein level, effect of gossypol (rat), 89  
Midtrimester abortion, use of osmotic cervical dilator, 215  
Milk volume and infant growth,  
    effect of ethinyl estradiol + levonorgestrel, 505  
    effect of depot-medroxyprogesterone acetate, 505  
    effect of dl-norgestrel, 505  
Morbidity of breast-fed children, effect of depot-medroxyprogesterone acetate  
    in lactating women, 523  
Morbidity risk, young adolescents undergoing elective abortion, 99  
Morphologic changes of endometrium, effect of norethisterone enanthate, 225  
Morphology, effect on blastocysts by CI-628 (mouse), 271  
Morphology and histology of cord, case reports of placental candidiasis, 555  
Morphometric changes of endometrium, effect of norethisterone enanthate, 225  
Motility of spermatozoa, effect of reserpine, 363  
Multiload, performance in women with previous cesarean section, 209  
Nafarelin (D-Nal(2) $\beta$ -GnRH), inhibition of ovulation by intranasal  
    administration, 107  
Natural Family Planning, epidemiologic review of aged gametes and adverse  
    pregnancy outcomes, 297  
Natural or barrier method users, microbiological and histological findings  
    in the fallopian tubes, 457

## CONTRACEPTION

- Nausea, effect of ethinylestradiol + norethisterone, 371  
NeoSampoon tablet, effect on metabolic activity of Ureaplasma urealyticum, 135  
Norethindrone, multicenter clinical trial of subcutaneous implants, 239  
Norethindrone level, use of norethindrone pellet implants, 239  
Norethindrone pellets, norethindrone + cholesterol, 239  
Norethisterone, dissolution rates of different crystal sizes, 371  
Norethisterone enanthate,  
    contraceptive efficacy of 60±5-day and 90±5-day regimens, 561  
    pharmacokinetics, pharmacodynamics and endometrial effects, 225  
    use in women with systemic lupus erythematosus, 29  
Norethisterone level,  
    after intramuscular injection of norethisterone enanthate, 225  
    use of injectable ethinylestradiol + norethisterone system, 371  
d-Norgestrel,  
    biological, microscopic and scanning electron microscopic investigations of effects (rabbit), 153  
    effect on fibrinolytic activity in plasma and vessel walls of hind leg (rat), 169  
    effect on release of tissue-type plasminogen activator, 355  
dl-Norgestrel, effect on milk volume and infant growth, 505  
d-Norgestrel level, after subcutaneous injection of d-norgestrel (rat), 169  
NORPLANT®, contraceptive subdermal implants, 391, 407, 413, 421, 431  
Nursing women, fertility regulation with progesterone implants, 311  
Oral contraceptive,  
    ethinylestradiol + gestoden, 575  
    ethinyl estradiol + levonorgestrel, 179, 421, 505  
    ethinyloestradiol + desogestrel, 61, 575  
    ethinyloestradiol + levonorgestrel, 61, 289  
    levonorgestrel, 29  
    mestranol + norethisterone, 421  
    dl-norgestrel, 505  
Oral contraceptive pill users, microbiological and histological findings in the fallopian tubes, 457  
Oral contraceptive use,  
    association with pelvic inflammatory disease, 1  
    prospective follow-up of women with suspected glucose intolerance, 197  
ORF 13811 (1RS, 4SR, 5RS-4-(5-hydroxy-4,8-dimethyl-7-nonenyl)-4-methyl-3,8-dioxabicyclo[3.2.1]octane-1-acetic acid, a synthetic analog of zoapatanol),  
    antifertility activity (variety of biological test systems), 39  
    pharmacological properties (variety of biological test systems), 39  
    uterotonic activity (guinea pig), 39  
Osmotic cervical dilator, clinical evaluations, 215  
Ovarian reaction, effect of norethisterone enanthate, 225  
Ovarian response, effect of norethindrone, 239  
Ovulation, effect of nafarelin, 107  
Partial thromboplastin time,  
    effect of ethinylestradiol + levonorgestrel, 421  
    effect of levonorgestrel, 421  
    effect of mestranol + norethisterone, 421  
Past history of pelvic inflammatory disease, relative risk of recurrence associated with IUD use, 1

## CONTRACEPTION

- Pelvic inflammatory disease,  
    association with abortion, 1  
    association with fertility regulating agents, 1  
    association with sterilization, 1  
    use of levonorgestrel-releasing IUD, 443  
    use of TCu 380Ag, 443
- PGF<sub>2 $\alpha$</sub>  (prostaglandin F<sub>2 $\alpha$</sub> )  
PGF<sub>2 $\alpha$</sub>  + urea, used with osmotic dilator or laminaria tent for midtrimester abortion, 215
- pH,  
    Betadine, 135  
    chemical intravaginal contraceptives, 135
- Pharmacodynamics, norethisterone enanthate, 225
- Pharmacokinetic parameters, effect of subcutaneous administration of various doses of levonorgestrel (rat), 599
- Pharmacokinetics,  
    effect of primaquine and chloroquine on ethynodiol + levonorgestrel, 289  
    ethynodiol, 289  
    levonorgestrel, 289  
    levonorgestrel (rat), 81, 599  
    norethisterone enanthate, 225  
    ST-1435, 381
- Pharmacokinetics of levonorgestrel, effect of dose (rat), 599
- Pharmacological properties, effect of ORF 13811 (variety of biological test systems), 39
- Phospholipids level, effect of levonorgestrel, 55
- Placental candidiasis,  
    case report occurring at term, 555  
    case report of copper 7 IUCD *in situ*, 555
- Plasminogen activator, regulatory effect of contraceptive steroids on release, 355
- Plasminogen level,  
    effect of ethynodiol + levonorgestrel, 421  
    effect of levonorgestrel, 421  
    effect of mestranol + norethisterone, 421
- Platelet abnormalities induced by estrogen, effect of vitamin E (rat), 279
- Platelet aggregation, effect of  $\alpha$ -tocopherol and ethynodiol administration with normal or vitamin E-deficient diet (rat), 279
- Platelet count,  
    effect of ethynodiol + levonorgestrel, 421  
    effect of levonorgestrel, 421  
    effect of mestranol + norethisterone, 421
- Platelet lipid biosynthesis, effect of  $\alpha$ -tocopherol and ethynodiol administration with normal or vitamin E-deficient diet (rat), 279
- Portal plasma, ST-1435 concentration after oral administration (rat), 143
- Postabortal contraception, immediate insertion of levonorgestrel implants, 431
- Postpartum IUD insertion, effect of insertion technique on expulsion rate, 327
- Prealbumin level,  
    effect of desogestrel, 73  
    effect of lynestrenol, 73

## CONTRACEPTION

- Pregnancy,  
progesterone pellets in lactating women, 311  
tubal sterilization with Filshie Clip, 339  
use of cervical cap, 115  
use of Copper T200 in lactating women, 311  
use of intranasal nafarelin, 107  
use of norethindrone pellet implants, 239
- Pregnancy rate,  
effect of insertion technique in postpartum IUD insertion, 327  
interval insertion of IUD in women with previous cesarean section, 209  
use of cavity rim cap, 331  
use of levonorgestrel-releasing IUD, 443  
use of norethisterone enantahate 60±5-day or 90±5-day schedule, 561  
use of TCu 380Ag, 443
- Pregnanediol level, effect of norethindrone, 239
- Pregnenolone level,  
effect of [D-Tryp<sup>6</sup>]LHRH ethylamide (dog), 483, 585  
effect of [D-Tryp<sup>6</sup>]LHRH ethylamide + testosterone (dog), 585
- Prescribed cavity rim cap, use effectiveness, 331
- Prescribed method of use, cavity rim cap, 331
- Primaquine, effect on pharmacokinetics of ethinylestradiol + levonorgestrel, 289
- Progesteragen contraceptives, use in women with systemic lupus erythematosus, 29
- Progesterone implants, fertility regulation in nursing women, 311
- Progesterone level,  
effect of levonorgestrel, 391, 431  
effect of nafarelin, 107  
effect of norethisterone enantahate, 225  
effect of [D-Tryp<sup>6</sup>]LHRH ethylamide (dog), 483, 585  
effect of [D-Tryp<sup>6</sup>]LHRH ethylamide + testosterone (dog), 585  
effect of tubal sterilization, 125  
use of progesterone pellets in lactating women, 311
- Prolactin level, effect of levonorgestrel, 391
- Prostaglandin (PG),  
15-keto-13,14-dihydro-PGF<sub>2α</sub>, 23  
PGF<sub>2α</sub>, 39
- Prostaglandin F<sub>2α</sub> (PGF<sub>2α</sub>),  
effect on cardiovascular pharmacology (rat, guinea pig), 39  
effect on uterine contractility (guinea pig), 39
- Prostate histology,  
effect of [D-Tryp<sup>6</sup>]LHRH ethylamide (dog), 483, 585  
effect of [D-Tryp<sup>6</sup>]LHRH ethylamide + testosterone (dog), 585
- Prostate weight,  
effect of [D-Tryp<sup>6</sup>]LHRH ethylamide (dog), 483, 585  
effect of [D-Tryp<sup>6</sup>]LHRH ethylamide + testosterone (dog), 585
- Prostatic steroid levels  
effect of [D-Tryp<sup>6</sup>]LHRH ethylamide (dog), 483, 585  
effect of [D-Tryp<sup>6</sup>]LHRH ethylamide + testosterone (dog), 585
- Protein level, effect of levonorgestrel, 407
- Proteins,  
effect of desogestrel, 73  
effect of lynestrenol, 73

## CONTRACEPTION

- Prothrombin time,
  - effect of ethinylestradiol + levonorgestrel, 421
  - effect of levonorgestrel, 421
  - effect of mestranol + norethisterone, 421
- Quinacrine, effect of intrauterine administration on genital tract morphology (monkey), 161
- Radioimmunoassay, levonorgestrel, 81
- Randomized study, TCu 380Ag and levonorgestrel-releasing IUD, 443
- Relative risk,
  - complication for adolescents undergoing elective abortion, 99
  - impaired glucose tolerance and diabetes mellitus with oral contraceptive use, 197
  - pelvic inflammatory disease associated with abortion as outcome of last pregnancy, 1
  - pelvic inflammatory disease associated with contraceptive use, 1
  - recurrent pelvic inflammatory disease associated with current IUD use, 1
- Removal of IUCD, influence on colonization of cervix by actinomycetes-like organisms, 535
- Removal rate,
  - effect of insertion technique in postpartum IUD insertion, 327
  - interval insertion of IUD in women with previous cesarean section, 209
- Reserpine (methyl reserpate, 3,4,5-trimethoxybenzoic acid ester),
  - effect of fertilizing capacity of spermatozoa, 363
  - effect of motility of spermatozoa, 363
- Return of fertility, following removal of levonorgestrel implants, 431
- Reversible inhibition of gonadal functions, [D-Tryp<sup>6</sup>]LHRH ethylamide (dog), 483
- Route of sterilization, influence on prognosis, 339
- Scanning electron microscopic investigation, effect of d-norgestrel (rabbit), 153
- Selective inhibition of spermatogenesis,
  - effect of [D-Tryp<sup>6</sup>]LHRH ethylamide (dog), 585
  - effect of [D-Tryp<sup>6</sup>]LHRH ethylamide + testosterone (dog), 585
- Sex ratio, epidemiologic review of Natural Family Planning, 297
- SHBG (sex hormone binding globulin)
- SHBG level,
  - effect of desogestrel, 73
  - effect of lynestrenol, 73
- Side effects,
  - norethindrone pellet implants, 239
  - use of cavity rim cap, 331
  - use of intranasal naftarelin, 107
  - use of norethisterone oenanthate, 561
- Sperm count,
  - effect of [D-Tryp<sup>6</sup>]LHRH ethylamide (dog), 483, 585
  - effect of [D-Tryp<sup>6</sup>]LHRH ethylamide + testosterone (dog), 585
- Spermatogenesis,
  - effect of [D-Tryp<sup>6</sup>]LHRH ethylamide (dog), 585
  - effect of [D-Tryp<sup>6</sup>]LHRH ethylamide + testosterone (dog), 585
- Spermatozoal fertilizing capacity, effect of reserpine, 363
- Spermatozoal metabolism, effect of (S)- $\alpha$ -chlorhydrin and 6-chloro-6-deoxyglucose (guinea pig), 261
- Spermicidal effect, ( $\pm$ )-gossypol, (+)-gossypol, (-)-gossypol and gossypolone, 253

## CONTRACEPTION

- Spontaneous abortion, epidemiologic review of Natural Family Planning, 297  
ST-1435 (16-methylene-17 $\alpha$ -acetoxy-19-nor-4-pregnene-3,20-dione),  
    intestinal absorption (rat), 143  
    pharmacokinetic observations, 381  
ST-1435 level,  
    after insertion of contraceptive vaginal ring containing ST-1435, 381  
    after insertion of subcutaneous capsules containing ST-1435, 381  
    after oral administration of ST-1435 (rat), 143  
Sterilization,  
    association with pelvic inflammatory disease, 1  
    experience in a free-standing clinic, 545  
    laparoscopic tubal rings, 125  
    Pomeroy's technique, 125  
    use of Filshe Clip Mark IV, 339  
Subdermal capsules, ST-1435, 381  
Survival probability, use of cervical cap, 115  
Suspected glucose intolerance, effect of oral contraceptive use, 197  
Systemic lupus erythematosus, use of progestagen contraceptives, 29  
Systemic venous plasma, SST-1435 concentration after oral administration  
    (rat), 143  
TC (total cholesterol)  
TC level,  
    effect of ethynodiol + desogestrel, 61  
    effect of ethynodiol + levonorgestrel, 61  
    effect of levonorgestrel, 55, 413  
TC/HDL-C ratio, effect of levonorgestrel, 413  
TCu 380Ag, effectiveness, 443  
Termination rate,  
    use of cavity rim cap, 331  
    use of levonorgestrel-releasing IUD, 443  
    use of TCu 380Ag, 443,  
Testicular steroid levels,  
    effect of [D-Tryp<sup>6</sup>]LHRH ethylamide (dog), 483, 585  
    effect of [D-Tryp<sup>6</sup>]LHRH ethylamide + testosterone (dog), 585  
Testis histology,  
    effect of [D-Tryp<sup>6</sup>]LHRH ethylamide (dog), 483, 585  
    effect of [D-Tryp<sup>6</sup>]LHRH ethylamide + testosterone (dog), 585  
Testis weight,  
    effect of [D-Tryp<sup>6</sup>]LHRH ethylamide (dog), 483, 585  
    effect of [D-Tryp<sup>6</sup>]LHRH ethylamide + testosterone (dog), 585  
Testosterone + [D-Tryp<sup>6</sup>,des-Gly-NH<sub>2</sub><sup>10</sup>]LHRH ethylamide, effect on  
    spermatogenesis (dog), 585  
Testosterone level,  
    effect of desogestrel, 73  
    effect of lynestrenol, 73  
    effect of [D-Tryp<sup>6</sup>]LHRH ethylamide (dog), 483, 585  
    effect of [D-Tryp<sup>6</sup>]LHRH ethylamide + testosterone (dog), 585  
Tetracycline, effect of intrauterine administration on genital tract  
    morphology (monkey), 161  
Thrombin time,  
    effect of ethynodiol + levonorgestrel, 421  
    effect of levonorgestrel, 421  
    effect of mestranol + norethisterone, 421

## CONTRACEPTION

- Thyroxine binding globulin level,  
    effect of desogestrel, 73  
    effect of lynestrenol, 73
- Time of sterilization, influence on prognosis, 339
- Time- and dose-dependent alterations of basal and LH-RH-stimulated LH release,  
    treatment with various hormonal contraceptives (rat), 467
- Tissue-type plasminogen activator, regulatory effect of contraceptive  
    steroids on release, 355
- $\alpha$ -Tocopherol acetate, effect on platelet lipid biosynthesis and aggregation  
    with normal or vitamin E-deficient diet (rat), 279
- Tolbutamide metabolism, effect of gossypol (rat), 89
- Tolerance, progesterone pellets in lactating women, 311
- Transferrin level, effect of levonorgestrel, 407
- Triglycerides level,  
    effect of ethynodiol + desogestrel, 61  
    effect of ethynodiol + levonorgestrel, 61  
    effect of levonorgestrel, 55, 413
- [D-Trypt<sup>6</sup>]LHRH ethylamide ([D-Trypt<sup>6</sup>,des-Gly-NH<sub>2</sub><sup>10</sup>]LHRH ethylamide,  
[D-Trypt<sup>6</sup>,des-Gly-NH<sub>2</sub><sup>10</sup>]LHRH ethylamide ([D-Trypt<sup>6</sup>]LHRH ethylamide),  
    effect on spermatogenesis (dog), 585  
    reversible inhibition of gonadal functions (dog), 483
- [D-Trypt<sup>6</sup>,des-Gly-NH<sub>2</sub><sup>10</sup>]LHRH ethylamide + testosterone, effect on  
    spermatogenesis (dog), 585
- Tubal occlusion, effect of intrauterine quinacrine and tetracycline  
    (monkey), 161
- Tubal sterilization,  
    evaluation of luteal changes, 125  
    laparoscopy and bipolar cauterization in a free-standing clinic, 545
- Tubal sterilization with Filshe Clip Mark IV, multicentre study, 339
- Urea + PGF<sub>2</sub> $\alpha$ , used with osmotic dilator or laminaria tent for  
    midtrimester abortion, 215
- Ureaplasma urealyticum, effect of chemical intravaginal contraceptives  
    and Befadine, 135
- Uterine contractility,  
    effect of ORF 13811 (guinea pig), 39  
    effect of PGF<sub>2</sub> $\alpha$  (guinea pig), 39
- Vaginal cytology,  
    effect of desogestrel, 73  
    effect of lynestrenol, 73
- Vessel walls of hind leg,  
    effect of ethynodiol on fibrinolytic activity (rat), 169  
    effect of d-norgestrel on fibrinolytic activity (rat), 169
- Vimule cervical cap, survey of use and efficacy, 115
- Vitamin A level, effect of ethynodiol + levonorgestrel and  
    multivitamin supplementation, 179
- Vitamin B-1 level, effect of ethynodiol + levonorgestrel and  
    multivitamin supplementation, 179
- Vitamin B-2 level, effect of ethynodiol + levonorgestrel and  
    multivitamin supplementation, 179
- Vitamin B-6 level, effect of ethynodiol + levonorgestrel and  
    multivitamin supplementation, 179
- Vitamin B-12 level, effect of ethynodiol + levonorgestrel and  
    multivitamin supplementation, 179
- Vitamin E, effect on platelet abnormalities induced by estrogen (rat), 279

## CONTRACEPTION

- Vitamin E level, effect of ethinyl estradiol + levonorgestrel and multivitamin supplementation, 179
- Vitamin E level in platelets and plasma, effect of  $\alpha$ -tocopherol and ethynodiol administration with normal or vitamin E-deficient diet (rat), 279
- Vitamin metabolism and effects of multivitamin supplementation, use of ethinyl estradiol + levonorgestrel, 179
- Weight of breast-fed children, effect of depot-medroxyprogesterone acetate in lactating women, 523
- Xanthurenic acid level, effect of ethinyl estradiol + levonorgestrel and multivitamin supplementation, 179